{"log_id": 2096737042713847416, "direction": 0, "words_result_num": 44, "words_result": [{"probability": {"variance": 2e-05, "average": 0.998282, "min": 0.973174}, "location": {"width": 801, "top": 140, "height": 39, "left": 190}, "words": "板减少症、血管炎和视觉障碍。在多数情况下,上述改变与本品的因果关系尚未确定"}, {"probability": {"variance": 1e-06, "average": 0.999446, "min": 0.994449}, "location": {"width": 589, "top": 174, "height": 33, "left": 221}, "words": "过敏反应罕见,包括瘙痒症、皮疹、血管源性水肿和多型红斑"}, {"probability": {"variance": 5e-06, "average": 0.998399, "min": 0.989266}, "location": {"width": 823, "top": 204, "height": 40, "left": 222}, "words": "曾有极罕见的肝炎、黄疸、肝酶升高的报道(通常与胆汁淤积相一致)。某些因病情较"}, {"probability": {"variance": 6.8e-05, "average": 0.996459, "min": 0.96317}, "location": {"width": 779, "top": 236, "height": 40, "left": 189}, "words": "重而住院的病例据报道与使用氨氯地平相关。在许多情况下,其因果关系不能确定"}, {"probability": {"variance": 7e-06, "average": 0.998533, "min": 0.984969}, "location": {"width": 823, "top": 269, "height": 40, "left": 222}, "words": "与其它的钙拮抗剂相似,以下的不良事件也有少数报道,但事件难以与基础疾病的自然"}, {"probability": {"variance": 9e-06, "average": 0.99851, "min": 0.9856}, "location": {"width": 737, "top": 302, "height": 36, "left": 188}, "words": "病程相区分,如:心肌梗塞、心律失常(包括室性心动过速和房颤)以及胸痛"}, {"probability": {"variance": 1e-06, "average": 0.999488, "min": 0.998248}, "location": {"width": 119, "top": 336, "height": 27, "left": 195}, "words": "【禁忌】"}, {"probability": {"variance": 8e-06, "average": 0.998781, "min": 0.986194}, "location": {"width": 500, "top": 371, "height": 29, "left": 231}, "words": "对二氢吡啶类药物或本品中任何成分过敏的病人禁用"}, {"probability": {"variance": 0, "average": 0.999736, "min": 0.999398}, "location": {"width": 115, "top": 402, "height": 26, "left": 196}, "words": "【注意事项】"}, {"probability": {"variance": 0.003339, "average": 0.989469, "min": 0.638177}, "location": {"width": 812, "top": 433, "height": 39, "left": 230}, "words": "1.警告:在开始使用钙拮抗剂治疗或增加剂量时,尤其是对那些有严重的冠状动脉阻"}, {"probability": {"variance": 0.000491, "average": 0.993717, "min": 0.886562}, "location": {"width": 856, "top": 466, "height": 39, "left": 186}, "words": "塞性疾病的患者,有心绞痛发作频率增加、时间延长和/或程度加重或发生急性心肌梗塞的"}, {"probability": {"variance": 1e-06, "average": 0.999127, "min": 0.996539}, "location": {"width": 350, "top": 500, "height": 26, "left": 185}, "words": "个例报道,其作用机制目前尚不清楚"}, {"probability": {"variance": 2.5e-05, "average": 0.997991, "min": 0.97486}, "location": {"width": 791, "top": 529, "height": 40, "left": 229}, "words": "2.本品的扩张血管作用是逐渐发生的,服用本品后发生急性低血压的情况罕有报道"}, {"probability": {"variance": 9.4e-05, "average": 0.996374, "min": 0.9504}, "location": {"width": 737, "top": 561, "height": 37, "left": 185}, "words": "然而,在严重的主动脉狭窄患者,本品与其它周围血管扩张剂合用时,应慎重"}, {"probability": {"variance": 0.000291, "average": 0.995069, "min": 0.910848}, "location": {"width": 556, "top": 595, "height": 35, "left": 228}, "words": "3.充血性心衰患者:充血性心衰患者使用钙拮抗剂应谨慎"}, {"probability": {"variance": 7.1e-05, "average": 0.997259, "min": 0.947674}, "location": {"width": 812, "top": 628, "height": 40, "left": 229}, "words": "在安慰剂对照的 PRAISE研究中,同时接受地高辛、利尿剂和ACEI治疗的心功能不全病人"}, {"probability": {"variance": 0.000451, "average": 0.991561, "min": 0.876589}, "location": {"width": 842, "top": 659, "height": 41, "left": 196}, "words": "( nyhaiii-iv级),联合本品治疗,随访平均14个月,未观察到对患者的生存率或发病率(指"}, {"probability": {"variance": 2.6e-05, "average": 0.997441, "min": 0.970876}, "location": {"width": 854, "top": 691, "height": 42, "left": 184}, "words": "致死性心率失常、急性心肌梗塞及由于心衰加重而住院的发生率)有负面的影响。在697名"}, {"probability": {"variance": 0.011651, "average": 0.969299, "min": 0.464656}, "location": {"width": 853, "top": 725, "height": 38, "left": 185}, "words": " NYHAII-III级心功能不全患者,8-12周的安慰剂对照临床研究中,通过测量运动耐量、左室"}, {"probability": {"variance": 1.1e-05, "average": 0.998036, "min": 0.984532}, "location": {"width": 610, "top": 756, "height": 37, "left": 183}, "words": "射血分数和临床症状等指标显示本品不会使患者的心衰症状加重"}, {"probability": {"variance": 0.000845, "average": 0.993369, "min": 0.820462}, "location": {"width": 791, "top": 787, "height": 39, "left": 224}, "words": "4.肝功能损害患者:与其他所有钙拮抗剂相同,在肝功能受损时本品的半衰期延长"}, {"probability": {"variance": 1e-06, "average": 0.999221, "min": 0.995361}, "location": {"width": 629, "top": 820, "height": 33, "left": 184}, "words": "但尚未确定相应的推荐剂量,因此,在这种情况下使用本品应谨慎"}, {"probability": {"variance": 6.2e-05, "average": 0.996929, "min": 0.962242}, "location": {"width": 783, "top": 852, "height": 39, "left": 254}, "words": "肾功能衰竭患者:仅10%的药物以原形由尿液排泄,氨氯地平血药浓度的改变与肾功"}, {"probability": {"variance": 0.000334, "average": 0.994587, "min": 0.894612}, "location": {"width": 841, "top": 882, "height": 41, "left": 184}, "words": "能损害程度无相关性。因此,对这些患者可以采用正常剂量。氨氯地平不能通过透析清除"}, {"probability": {"variance": 0, "average": 0.999645, "min": 0.998436}, "location": {"width": 244, "top": 919, "height": 26, "left": 188}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 5.2e-05, "average": 0.997583, "min": 0.95683}, "location": {"width": 791, "top": 948, "height": 42, "left": 246}, "words": "动物试验中,在推荐人用最大量的50倍剂量,本品除引起大鼠分娩延迟和滞产外,未"}, {"probability": {"variance": 5.6e-05, "average": 0.996616, "min": 0.96648}, "location": {"width": 853, "top": 981, "height": 40, "left": 183}, "words": "显示任何生殖毒性。本品用于妊娠期或哺乳期的安全性尚未确定。因此,仅在无其他更安全"}, {"probability": {"variance": 1e-06, "average": 0.999225, "min": 0.995898}, "location": {"width": 584, "top": 1015, "height": 33, "left": 183}, "words": "的代替药物和疾病本身对母子的危险性更大时才推荐使用本品"}, {"probability": {"variance": 0, "average": 0.999385, "min": 0.998462}, "location": {"width": 116, "top": 1048, "height": 26, "left": 190}, "words": "【儿童用药】"}, {"probability": {"variance": 2e-06, "average": 0.998336, "min": 0.995376}, "location": {"width": 304, "top": 1081, "height": 28, "left": 247}, "words": "未进行该项试验且无可参考文献"}, {"probability": {"variance": 0.000383, "average": 0.99059, "min": 0.946842}, "location": {"width": 117, "top": 1114, "height": 26, "left": 189}, "words": "【老年用药】"}, {"probability": {"variance": 0, "average": 0.999372, "min": 0.997295}, "location": {"width": 789, "top": 1144, "height": 41, "left": 246}, "words": "本品血药浓度的达峰时间在老年和年轻患者中是相似的,老年患者药时曲线下面积"}, {"probability": {"variance": 8.4e-05, "average": 0.996168, "min": 0.96323}, "location": {"width": 837, "top": 1179, "height": 38, "left": 196}, "words": "AUC)增加和消除半衰期的延长使消除率有下降趋势。有报导在接受相似剂量的氨氯地平"}, {"probability": {"variance": 8.4e-05, "average": 0.997668, "min": 0.941001}, "location": {"width": 852, "top": 1211, "height": 40, "left": 181}, "words": "时,老年患者具有与年轻患者相同的良好耐受性。因此,老年患者可用正常剂量。但开始宜"}, {"probability": {"variance": 3e-06, "average": 0.998764, "min": 0.99466}, "location": {"width": 258, "top": 1247, "height": 29, "left": 182}, "words": "用较小剂量,再渐增量为妥"}, {"probability": {"variance": 2e-06, "average": 0.998394, "min": 0.994816}, "location": {"width": 159, "top": 1280, "height": 27, "left": 188}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.004194, "average": 0.98311, "min": 0.634133}, "location": {"width": 810, "top": 1309, "height": 41, "left": 223}, "words": "本品与下列药物的合用是安全的:噻嗪类利尿剂、β-肾上腺素能受体阻滞剂、血管紧"}, {"probability": {"variance": 1.9e-05, "average": 0.998523, "min": 0.972936}, "location": {"width": 849, "top": 1343, "height": 39, "left": 181}, "words": "张素转化酶抑制剂、长效硝酸酯类药物、舌下含服硝酸甘油、非甾体类抗炎药、抗生素和口"}, {"probability": {"variance": 0, "average": 0.999947, "min": 0.999898}, "location": {"width": 89, "top": 1379, "height": 26, "left": 180}, "words": "服降糖药"}, {"probability": {"variance": 9e-06, "average": 0.997994, "min": 0.988107}, "location": {"width": 810, "top": 1408, "height": 41, "left": 221}, "words": "对健康志愿者的研究显示本品与地高辛合用不改变血清中地高辛浓度和地高辛的肾清"}, {"probability": {"variance": 2e-06, "average": 0.998864, "min": 0.994282}, "location": {"width": 454, "top": 1445, "height": 29, "left": 179}, "words": "除率,与西咪替丁合用不改变本品的药代动力学"}, {"probability": {"variance": 6e-05, "average": 0.997279, "min": 0.951738}, "location": {"width": 807, "top": 1477, "height": 37, "left": 224}, "words": "用人血浆进行的体外研究数据显示本品不影响地高辛、苯妥英钠、华法林或吲哚美辛的"}, {"probability": {"variance": 5e-06, "average": 0.998827, "min": 0.993396}, "location": {"width": 153, "top": 1512, "height": 25, "left": 180}, "words": "血浆蛋白结合率"}, {"probability": {"variance": 1.2e-05, "average": 0.998404, "min": 0.980287}, "location": {"width": 810, "top": 1540, "height": 40, "left": 222}, "words": "在男性健康志愿者研究中,本品与华法林合用没有显著改变华法林对于凝血酶原时间的"}], "language": 3}